| Similar Articles |
|---|
 |
Pharmaceutical Executive
December 1, 2005
Anthony Tao |
The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late?   |
The Motley Fool
December 1, 2008
Brian Orelli |
Obama Can't Save Stem Cell Companies While government-sponsored research on embryonic stem cells might eventually help scientists better understand all stem cells, it's not likely to help the companies right now. |
The Motley Fool
September 29, 2010
Brian Orelli |
Careful What You Wish For, Stem Cell Investors Investors seem to have forgotten about fundamentals. |
The Motley Fool
May 2, 2011
Brian Orelli |
StemCells Up for All the Right Reasons Federal funding doesn't matter for most stem cell companies. |
Bio-IT World
August 2005
Maureen McDonough |
U.K. Framework Offers Stem Cells a Future The United Kingdom has managed to cut through the noise surrounding stem cell research, creating a regulatory framework that fosters an environment of international collaboration and excellent R&D programs. And they try to do it all in an ethical way. |
Popular Mechanics
March 2006
Jeff Wise |
Fighting Fire With Fire By recreating an extinct virus that killed as many as 50 million people, scientists race to defeat avian flu before it evolves into a deadlier form. |
Geotimes
April 2005
David B. Williams |
Mass Extinction, Massive Problem The great debate continues over the Great Dying -- the largest of all mass extinctions, which occurred 250 million years ago. The latest round of research casts doubt on an extraterrestrial impact as the cause of the extinction event. |
Chemistry World
April 6, 2009
Rebecca Trager |
US funding boost - a threat to EU science? These developments have raised some concern about the possibility of a 'brain drain' from Europe to the US, as these falling barriers have quickly made the region a more appealing destination for researchers. |
The Motley Fool
November 28, 2007
Brian Orelli |
Stem Your Expectations of Stem-Cell Discoveries Making "stem" cells out of skin cells isn't all it's cracked up to be. The recent discovery has a long way to go before it can catch up to the research currently being done with stem cells. |
BusinessWeek
January 10, 2005
Bruce Einhorn |
Asia Is Stem Cell Central Singapore isn't the only country in the region trying to profit from the U.S. restrictions. Australia, China, India, Japan, and South Korea all see stem cell research as a way to get ahead in biotech. |
Scientific American
December 2008
Tim Hornyak |
Turning Back the Cellular Clock: A Farewell to Embryonic Stem Cells? Shinya Yamanaka discovered how to revert adult cells to an embryonic state. These induced pluripotent stem cells might soon supplant their embryonic cousins in therapeutic promise |
Salon.com
December 29, 2000
Arthur Allen |
Will Thompson, Bush clash over human embryo research? The HHS nominee supports it, but right-to-lifers want it stopped.... |
Managed Care
February 2005
Jack McCain |
Managed Care (and Everyone Else) Unprepared for the Next Killer Flu Could avian flu give rise to a pandemic that might rival the fearsome Spanish flu? Is the nation ready? Health plans may be called upon to administer vaccinations and identify high-risk patients, but what about he millions of Americans who lack health insurance? |
Pharmaceutical Executive
October 1, 2012
Ben Comer |
Stem Cells: A Promise Deferred? Ideology, politics, and a stilted political debate may be causing pharma to overlook the potential of emerging stem cell therapies in fostering a new generation of cures. |
Scientific American
March 2006
Sara Beardsley |
Down in Flames Can stem cell research recover from Woo Suk Hwang? |
Chemistry World
August 15, 2007
John Bonner |
Chemists Claim Biological Alchemy South Korean chemists say they have turned muscle cells from the sole of a human foot into something akin to stem cells, using a simple molecule called neurodazine. |
BusinessWeek
September 23, 2010
Rob Waters |
Stem Cells That Save Big Pharma a Bundle Drugmakers hope to save big by using stem cells to test drugs for dangerous side effects long before costly human trials are needed. |
BusinessWeek
May 24, 2004
Arlene Weintraub |
Repairing The Engines Of Life Can research into stem cells and other advanced techniques heal ailing hearts and brains? U.S. labs are hamstrung by the federal government. |
Geotimes
October 2006 |
Geocatastrophes Catastrophe and Opportunity in an Ancient Hot-House Climate... When the Mediterranean Dried Up: Forensics of a Geocatastrophe... The Great Death: Redefining a Mass Extinction... |
BusinessWeek
January 23, 2006
Arlene Weintraub |
A "Body Blow" To Stem Cell Research Funding for stem cell research in the U.S. wasn't so hot even before the Korean scandal broke. |
Bio-IT World
Dec 2005/Jan 2006
Maureen McDonough |
The Century of the Cell Like most new life science industries, the stem cell business landscape looks like a maze. There are many paths, turns, and dead-ends, but it is quite possible that there will be more than one route to the finish line. |
Bio-IT World
April 2006 |
Virtual Stem Cell Laboratory Goes Live Children's Hospital in Boston's Virtual Stem Cell Laboratory web site allows online visitors to manipulate and investigate a "living" culture of embryonic stem cells. |
The Motley Fool
January 31, 2011
Brian Orelli |
Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet. |
The Motley Fool
August 27, 2007
Brian Orelli |
Repairing a Broken Heart Stem cells may be the new cure. If research continues on track, Geron expects to ask FDA to start clinical trials late next year or in early 2009. Investors, take note. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
A Boost for Broken Hearts? The Institute of Regenerative Medicine in Barbados is convinced that stem cells from fetuses can repair cardiac damage. |
BusinessWeek
October 24, 2005
John Carey |
New Vaccines For A Pandemic Using DNA, vast amounts of flu vaccine could be made quickly. But will the drugs work? |
The Motley Fool
June 21, 2005
Brian Gorman |
Stem Cell Chatter Despite the promise suggested by early studies, embryonic stem cell research remains highly speculative. More concrete results, not the amount of cash being poured into research, are the best basis for investing decisions. |
BusinessWeek
January 9, 2006
Carol Matlack |
Preventing The Pandemic France's Sanofi Pasteur is already signing contracts for an avian flu vaccine. |
BusinessWeek
July 26, 2004
Arlene Weintraub |
The Stem-Cell Flap: Simmer Down Advocates are overstating stem cells' near-term ability to treat grave illnesses. In doing so, they not only distort the science; the hopes they raise among many people who are sick today are also sure to be dashed. |
The Motley Fool
February 2, 2005
Rich Duprey |
Aastrom to Leap Into Trials The biotech firm advances to the next stage of clinical studies in stem cell research. Investors, take note. |
The Motley Fool
August 31, 2007
Brian Orelli |
A Stem-Cell Primer Public funding from states could help companies doing stem cell research. Read about Geron, StemCells, Osiris Therapeutics, ViaCell and Invitrogen, companies that may profit from the increased public spending. |
The Motley Fool
May 3, 2005
Charly Travers |
Is Geron a Rule Breaker? At the forefront of stem cell research, can the company live up to its lofty potential? Geron's science is hot. Its stock is not. |
Inc.
February 2005
Patrick J. Sauer |
The State of Stem Cell Research Californians are hoping that stem cell research will do for them what the invention of the car did for Michigan. |
Scientific American
July 2008
Sally Lehrman |
Dolly's Creator Moves Away from Cloning and Embryonic Stem Cells Like many stem cell pioneers, Ian Wilmut, the creator of Dolly the sheep, has jumped to an alternative approach. Is this the beginning of the end for embryonic cloning? |
Chemistry World
February 23, 2015
Phillip Broadwith |
Europe approves stem cell therapy A stem cell treatment for severe cornea damage has been granted conditional approval by the European commission. |
BusinessWeek
July 18, 2005 |
Research and "False Expectations" While Korean scientist Hwang Woo Suk is eager to see practical applications of his work, he warns that optimism needs to be qualified by reality. |
The Motley Fool
March 16, 2006
Rich Duprey |
Avian Flu Ruffling Feathers Roche Pharmaceuticals boosts anti-flu drug production to quiet calls for generics. While the situation bears watching for now, it's not necessarily something for investors to get their feathers ruffled about. |
Scientific American
April 2009
Philip Yam |
Updates: Whatever Happened to Melting Glaciers and Ocean Levels? New details are emerging on how the melting poles could raise ocean heights... Fingerprint science... Stem cell progress... The far side of the moon... |
The Motley Fool
July 26, 2004
Brian Gorman |
Stem Cell Researcher a Risk Geron could benefit from a new U.S. president, but in the end, studies of embryonic stem cells may or may not yield breakthroughs, so buying their stock now would be a gamble. |
Chemistry World
May 14, 2008
Simon Hadlington |
Bird Flu's Drug Resistance Mapped UK scientists have shown exactly why a mutant version of the deadly bird flu virus H5N1 becomes resistant to the drug oseltamivir - marketed as Tamiflu. |
The Motley Fool
November 9, 2004
Charly Travers |
Are Stem Cells a Rule Breaker? Does the science offer real hope or just hype? Biotech investors take on enough risk in the normal course of drug development that they do not need to worry about whether or not the underlying technology even works. |
Bio-IT World
July 15, 2003
Kevin Davies |
Stem Cell Suicide The International Society for Stem Cell Research must engage in a political discourse to salvage the hope of embryonic stem cell research. |
HHMI Bulletin
Aug 2011
Cassandra Willyard |
A Faster Knockout With a virus, a needle, and an ultrasound machine, researchers have drastically cut the time it takes to disable a gene in mice. |
Pharmaceutical Executive
March 1, 2007
Sarah Houlton |
Global Report: Ready ... Set ... The European Parliament has launched a formal process for assessing therapies developed through stem-cell research. Ethical issues that have wrangled US regulators, though, still need attention. |
Popular Mechanics
September 2006
Ben Harder |
Seeking Immunity Pathogens like West Nile virus show no respect for borders. But a new class of vaccines may soon keep them in check. |
The Motley Fool
April 14, 2008
Brian Orelli |
Stem Cells Show Off The FDA moves closer to setting up stem cell clinical trials, setting guidelines that put treatment safety first and foremost. |
| Knowledge@Wharton |
Bettering Ourselves Through Biotech: Greater Productivity, Sharper Memories, Hair Feathers Beefing up muscle without steroids or hormones; rejuvenating damaged skin and heart tissue; ratcheting up memory function. Therapies that promise to enhance human abilities are nearing the marketplace. Funding, however, is hard to come by these days. |
Chemistry World
February 21, 2013
James Urquhart |
New direction for flu drugs Researchers have developed a new class of anti-flu drug that could prevent new virus strains developing resistance and help control future pandemics while more effective vaccines are prepared. |
Scientific American
January 17, 2007
Charles Q. Choi |
A Stroke for Stem Cells The brain becomes a target in stem cell clinical trials. |
Geotimes
July 2004
Megan Sever |
Possible P/T Impact Crater A group of scientists now says they have uncovered a crater that may be responsible for the mass extinction at the end of the Permian, and their results are inciting a new flurry of controversy. |
